Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00219622 | A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease | PHASE2 | COMPLETED | 300 | — | — | May 1, 2004 | Jul 1, 2005 | Nov 7, 2012 | 40 | United States, Argentina +4 |
| Name | Type | Description |
|---|---|---|
| tofimilast | DRUG | - |
Inclusion Criteria: * Moderate-severe COPD (GOLD 2003 definition) * Smoking history of at least 10 pack-years Exclusion Criteria: * Any significant co-morbid disease, particularly cardiovascular * Use of any maintenance therapy except short acting bronchodilators